Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

NCT ID: NCT04902625

Last Updated: 2023-05-30

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 116 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-21
• Study Completion Date: 2025-03-31

Brief Summary

Although bariatric surgery is currently the most effective treatment for morbid obesity, weight regain occurs in 16-37% of the patients (1). Weight regain is not regularly treated with antiobesity medications (AOMs).

Mysimba (Contrave in US) is a AOM, it is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification. Bupropion is a mild reuptake inhibitor of dopamine and norepinephrine. Naltrexone, an opioid antagonist has minimum effect on weight loss on its own. Naltrexone is thought to block the inhibitory effects of opioid receptors activated by the β-endorphin released in the hypothalamus that stimulates feeding, thus allowing the inhibitory effects of α-melanocyte stimulating hormone to reduce food intake. In patients with obesity usage of Naltrexone/Bupropion (NB) results in up to 8.2% weight loss (2). There is some evidence that also in bariatric patients with weight regain NB leads to additional weight loss (3, 4).

At the Nederlandse Obesitas Kliniek (NOK) weight regain at follow-up is currently treated with the Back on Track (BOT) program. The BOT program is an extra intervention our clinic provides for the patients who have weight regain after surgery, this is part of our standard care program.

The primary objective is to study the effect of naltrexone/bupropion in combination with the BOT module on successful weight loss(>5% weight loss) after 22 weeks in patients with weight regain after bariatric surgery, compared to the regular BOT module.

Detailed Description

Throughout the years it has become clear that lifestyle intervention is the cornerstone for all types of bariatric treatment. Educating patients about behaviour, physical activity and intake strategies will help built a skills set, which patients can fall back on throughout their lives. Without additional lifestyle intervention a non-surgical, pharmacological or surgical treatment will be less effective. (5, 6) Besides lifestyle interventions, adjuvant pharmacological treatment has also proven to be effective in maintaining adequate weight loss. Pharmacological treatment is mostly performed in patients who are not eligible for bariatric surgery but do suffer from obesity and related comorbidities. Patients with a Body Mass Index(BMI) of ≥ 30kg/m2 or a BMI ≥ 27kg/m2 with an obesity-related comorbidity are advised to use pharmacological treatment. (7) In general the pharmacologic treatment affects appetite and therefore causes weight loss, provided that lifestyle interventions are added to the treatment.

For patients with a BMI of ≥ 40kg/m2 or a BMI ≥ 35kg/m2 with comorbid conditions bariatric surgery is advised. There is a variety of surgical treatment options, with Sleeve Gastrectomy (SG) and the Roux-en-Y gastric bypass (RYGB) being the most common. (8) An alteration of the gastro-intestinal tract is performed, which causes a change in gut hormones, bile acids and microbiota. These changes also have their effect on appetite and energy consumption causing an even higher weight reduction. (9) Although lifestyle interventions are the cornerstone of obesity treatment, bariatric surgery has proven to be a superior treatment. (9-11) Besides a positive effect on weight, bariatric surgery also has a positive effect on comorbidities, such as type 2 diabetes, hypertension, cancer incidence, cardiovascular events and cardiovascular deaths. (9, 10, 12-14) All in all we can state that bariatric surgery currently is the most effective treatment for patients suffering from morbid obesity.

Even though bariatric surgery is the most effective treatment, not all patients maintain their weight loss. As mentioned before weight regain occurs in 16-37% of the patients. (1) Currently these patients can be treated in our clinic with an extra module, the Back On Track (BOT) module. The BOT module consists of 4 extra sessions, 3 with the physiotherapist, psychologist or dietitian, and 1 with the medical doctor. During these sessions lifestyle modifications will once again be the main focus. A study performed with data from our own clinic shows an overall stabilisation of weight after this module. The regained weight will not be lost with the help of this module. Therefore other options should be explored.

One of the possibilities is the use of medication, in combination with lifestyle interventions (BOT module), to not only cause stabilisation of weight, but also weight loss at the end of our module.

Pharmacological therapy with other medication in post-bariatric patients is described to be a viable option. As described in the review performed by Sudlow et al, different medical options are being investigated. (15) At the moment most research has been focussing on pre-operative use of medication. In this review only four out of 20 studies described post-operative use of medication. Of these four only two studies researched the effect of naltrexone and bupropion combined in post-bariatric patients. Although these studies only have a small amount of participants (e.g. n=10), they do show a possible positive effect on weight loss. (3, 4, 15) Since there is a lack of research on the effect of pharmacotherapy as an addition to lifestyle interventions in post-bariatric patients, no clear guidelines can be created at the moment. (16)

Mysimba (Contrave in US) is Anti-Obesity Medication (AOM), it is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release. Naltrexone, mostly used for treatment of alcohol and opioid dependence, is thought to block the inhibitory effects of opioid receptors activated by the β-endorphin released in the hypothalamus that stimulates feeding, thus allowing the inhibitory effects of α-melanocyte stimulating hormone to reduce food intake. Bupropion is a mild reuptake inhibitor of dopamine and norepinephrine, which is used for treatment of depression and later for smoking cessation. On their own the effect on weight loss is minimal, when combined their effect on weight loss is synergistically positive. When combined with lifestyle interventions most successful results will be obtained.

In patients with obesity usage of Naltrexone/Bupropion (NB) has a stronger effect and results in up to 8.2% weight loss (2). A study performed by Apovian shows a significant difference in successful weight loss after 4 weeks, when comparing patients who use NB to patients with only lifestyle modifications. Their study had a follow-up period of 56 weeks with a extra measure timepoint at 28 weeks. All patients were measured and monitored every 4 weeks. The results at 4 weeks already showed a significant difference with the placebo group. (2) Furthermore, in a study conducted by Greenway et al after 16 weeks of follow up a significant difference in successful weight loss was observed. (17) So far not many studies have been conducted in post-bariatric patients. Even though the results thus far are scarce, they are promising. Two studies, both with a study population of 10, showed a positive result of around 5% more weight loss in post-bariatric patients. (3, 4)

In this study we will examine the effect of 2 tablets of Mysimba 8/90mg 2 times daily as addition to the Back On Track module for patients with weight regain after bariatric surgery.

Conditions

Obesity, Morbid; Bariatric Surgery Candidate; Medication Persistence

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Naltrexone-Bupropion combination

The patients in this arm will receive 2 tablets of naltrexone-bupropion 8/90mg 2 times daily in combination with the Back On Track module.

Group Type: ACTIVE_COMPARATOR

Naltrexone-Bupropion Combination

Intervention Type: DRUG

Naltrexone-bupropion will be added to the BOT module in the interventional arm.

Control

The patients is this arm will only participate in the Back On Track module and will not receive any investigational or placebo product.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Naltrexone-Bupropion Combination

Naltrexone-bupropion will be added to the BOT module in the interventional arm.

Intervention Type: DRUG

Other Intervention Names

Mysimba; Contrave

Eligibility Criteria

Inclusion Criteria

• BMI before surgery was ≥ 35,0 kg/m2
• Patient has undergone a primary banded/non-banded Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG)
• Gaining more than 5% weight after reaching plateau phase of lowest weight

Exclusion Criteria

• Anatomical or surgical abnormalities for which revisional surgery is indicated.
• Use of the following medication Monoamino-oxidase inbibitors (MAO), selective serotonin reuptake inhibitor (SSRI), Tricyclic antidepressants (TCA), haloperidol, risperidone, opioids, antiarrhythmics, betablockers, antiviral medication (HIV)
• Pregnancy or breastfeeding
• Patients suffering from:

• unregulated hypertension
• a tumour in the central nervous system
• severe liver failure
• end stage kidney failure
• Patients suffering from or with a history of insults
• Patients with a history of:

• bipolar disease
• bulimia or anorexia nervosa
• Patients withdrawing from alcohol or benzodiazepines
• Patients who are not able to understand the informed consent form and patient information.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nederlandse Obesitas Kliniek

UNKNOWN

Sponsor Role: collaborator

Zuyderland Medisch Centrum

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jan Willem Greve, MD, PhD, professor

Role: PRINCIPAL_INVESTIGATOR

Nederlandse Obesitas Kliniek Zuid

Locations

Zuyderland Medical Center

Heerlen, Limburg, Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

Marijn TF Jense, MD

Role: CONTACT

m.jense@zuyderland.nl

088-4599719

Valerie M Monpellier

Role: CONTACT

vmonpellier@obesitaskliniek.nl

Facility Contacts

Marijn Jense

Role: primary

m.jense@zuyderland.nl

Other Identifiers

NOK0023

Identifier Type: -

Identifier Source: org_study_id